Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRINCETON, N.J., July 21, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the United States Patent...
-
PRINCETON, N.J., May 22, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that Daniel J. O'Connor,...
-
PRINCETON, N.J., May 21, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Fred J....
-
PRINCETON, N.J. and SAN DIEGO, May 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a non-exclusive...
-
PRINCETON, N.J., May 6, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Thomas W....
-
Advaxis Announces Closing Public Offering of Common Stock With Gross Proceeds Totaling $53.2 Million
PRINCETON, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) a clinical-stage cancer immunotherapy company, today announced the closing of its previously announced underwritten public...
-
PRINCETON, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten...
-
PRINCETON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced that it intends to offer and sell shares of its common...
-
ADXS-PSA Patent Covers a Recombinant Listeria Strain Encoded with Recombinant Fusion Peptide of KLK3 Peptide Linked to Non-KLK3 Peptide ADXS-HER2 Patent Covers Method of Use in Treating HER2/Neu...
-
ADXS-HPV Combined with Anti-OX40 or Anti-GITR Antibodies Demonstrates Tumor Growth Inhibition and Prolonged Survival in a Preclinical Study ADXS-HER2 in Combination with Palliative Radiation...